Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Clinical Rheumatology
Published in: Clinical Rheumatology 10/2011

01-10-2011 | Case Based Review

Methotrexate-induced pulmonary toxicity in psoriatic arthritis (PsA): case presentation and literature review

Authors: Federico Rondon, Odilio Mendez, Nestor Spinel, Carlos Ochoa, Cristian Saavedra, Edgar Penaranda, Ignacio Garcia-Valladares, Luis R. Espinoza, Antonio Iglesias-Gamarra

Published in: Clinical Rheumatology | Issue 10/2011

Login to get access

Abstract

A 45-year-old female with a 4-week history of psoriatic arthritis developed cough, fever, and progressive shortness of breath 2 weeks following initiation of methotrexate therapy. High resolution CT of chest revealed bilateral basal interstitial involvement and diffuse ground glass opacities. Patient, though, died despite immediate discontinuation of methotrexate and initiation of treatment with IV methylprednisolone and cyclophosphamide. Post-mortem examination showed diffuse interstitial pulmonary fibrosis. Methotrexate-induced pulmonary toxicity is a serious event, unpredictable, and unusual, especially in patients with psoriatic arthritis, and although reversible, it may be fatal.
Literature
1.
Pincus T, Yazici Y, Sokka T, Aletaha D, Smolen JS (2003) Methotrexate as the “anchor drug” for the treatment of early rheumatoid arthritis. Clin Exp Rheumatol 21:179–185
2.
La Montagna G, Tirri R, Vitello R et al (2006) Safety of methotrexate in rheumatoid arthritis: a retrospective cohort study in clinical practice. Reumatismo 58:261–267PubMed
3.
Van Ede AE, Laan RF, Blom HJ, DeAbreu RA, van de Putte LB (1998) Methotrexate in rheumatoid arthritis: an update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 27:277–292PubMedCrossRef
4.
Verstappen SM, Bakker MF, Heurkens AH et al (2010) Adverse events and factors associated with toxicity in patients with early rheumatoid arthritis treated with methotrexate tight control therapy: the CAMERA study. Ann Rheum Dis 69:1044–1048PubMedCrossRef
5.
Kremer JM, Alarcon GS, Weinblatt ME et al (1997) Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review. Arthritis Rheum 40:1829–1837PubMedCrossRef
6.
Clarysse AM, Cathey WJ, Cartwright GE, Wintrobe MM (1969) Pulmonary disease complicating intermittent therapy with methotrexate. JAMA 209:1861–1868PubMedCrossRef
7.
Cannon GW, Ward JR, Clegg DO, Samuelson CO, Abbott TM (1983) Acute lung disease associated with low-dose pulse methotrexate therapy in patients with rheumatoid arthritis. Arthritis Rheum 26:1269–1274PubMedCrossRef
8.
Engelbrecht JA, Calhoon SL, Scherrer J (1983) Methotrexate pneumonitis after low-dose therapy for rheumatoid arthritis. Arthritis Rheum 26(10):1275–1278PubMedCrossRef
9.
Black RL, O’Brien WM, Vanscott EJ, Auerbach R, Eisen AZ, Bunin JJ (1964) Methotrexate therapy on psoriatic arthritis: a double blind study on 21 patients. JAMA 189:743–747PubMed
10.
Borchers AT, Keen CL, Cheema GS, Gershwin ME (2004) The use of methotrexate in rheumatoid arthritis. Semin Arthritis Rheum 34:465–483PubMedCrossRef
11.
Lateef O, Shakoor N, Balk RA (2005) Methotrexate pulmonary toxicity. Expert Opin Drug Saf 4:723–730PubMedCrossRef
12.
Chikura B, Sathi N, Lane S, Dawson JK (2008) Variation in immunological response in methotrexate-induced pneumonitis. Rheumatology 47:1647–1650PubMedCrossRef
13.
Kim YJ, Song M, Ryu JC (2009) Inflammation in methotrexate-induced pulmonary toxicity occurs via the p38 MAPK pathway. Toxicology 27:183–190CrossRef
14.
Alarcon GS, Kremer JM, Macaluso M et al (1997) Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case-control study. Methotrexate-Lung Study Group. Ann Intern Med 127:356–364PubMed
15.
Shidara K, Hoshi D, Inoue E et al (2010) Incidence of and risk factors for interstitial pneumonia in patients with rheumatoid arthritis in a large Japanese observational cohort, IORRA. Mod Rheumatol 20:280–286PubMedCrossRef
16.
Habib HM, Eisa AA, Arafat WR, Marie MA (2011) Pulmonary involvement in rheumatoid arthritis patients. Clin Rheumatol 30:217–221PubMedCrossRef
17.
Belzunegui J, Intxausti JJ, De Dios JR et al (2001) Absence of pulmonary fibrosis in patients with psoriatic arthritis treated with weekly low-dose methotrexate. Clin Exp Rheumatol 19:727–730PubMed
18.
Israel CW, Wegener M, Adamek RJ, Bitsch T, Weber K, Ricken D (1995) Severe pneumonitis as a complication of low-dose methotrexate therapy in psoriasis-associated polyarthritis. Dtsch Med Wochenschr 120:603–608PubMedCrossRef
19.
Salaffi F, Manganelli P, Carotti M, Subiaco S, Lamanna G, Cervini C (1997) Methotrexate-induced pneumonitis in patients with rheumatoid arthritis and psoriatic arthritis: report of five cases and review of the literature. Clin Rheumatol 16:296–304PubMedCrossRef
20.
Mazokopakis E, Katsogridakis K, Koutsopoulos A et al (2004) Fatal methotrexate-induced pneumonitis in a psoriatic patient. Mil Med 169:298–300PubMed
21.
Balbir-Gurman A, Guralnik L, Best LA et al (2009) Accelerated pulmonary nodulosis and sterile pleural effusion in a patient with psoriatic arthropathy during methotrexate therapy: a case report. J Clin Rheumatol 15:29–30PubMedCrossRef
22.
Manuel A, Jones Q, Wiggins J (2010) Multiple pulmonary nodules in a male with psoriatic arthritis. Eur Respir Rev 19:164–165PubMedCrossRef
23.
Gutierrez-Urena S, Molina JF, Garcia CO, Cuellar ML, Espinoza LR (1996) Pancytopenia secondary to MTX therapy in rheumatoid arthritis. Arthritis Rheum 39:272–276PubMedCrossRef
24.
Arakawa H, Yamasaki M, Kurihara Y, Yamada H, Nakajima Y (2003) Methotrexate-induced pulmonary injury: serial CT findings. J Thorac Imaging 18:231–236PubMedCrossRef
25.
LeMense GP, Sahn SA (1994) Opportunistic infection during treatment with lower dose methotrexate. Am J Respir Crit Care Med 150:258–260PubMed
26.
Cannon GW (1997) Methotrexate pulmonary toxicity. Rheum Dis Clin N Amer 23:917–937CrossRef
27.
Searle G, McKendry (1997) Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature. J Rheumatol 14:1164–1171
28.
Kremer JM, Alarcon GS, Alexander RW et al (1995) Methotrexate (MTX) lung toxicity: clinical features of thirty-seven cases from seven rheumatology practices. Arthritis Rheum 37:s205
29.
Carson CW, Cannon GW, Egger MJ, Ward JR, Clegg DO (1987) Pulmonary disease during the treatment of rheumatoid arthritis with low dose pulse methotrexate. Semin Arthritis Rheum 16:186–195PubMedCrossRef
Metadata
Title
Methotrexate-induced pulmonary toxicity in psoriatic arthritis (PsA): case presentation and literature review
Authors
Federico Rondon
Odilio Mendez
Nestor Spinel
Carlos Ochoa
Cristian Saavedra
Edgar Penaranda
Ignacio Garcia-Valladares
Luis R. Espinoza
Antonio Iglesias-Gamarra
Publication date
01-10-2011
Publisher
Springer-Verlag
Published in
Clinical Rheumatology / Issue 10/2011
Print ISSN: 0770-3198
Electronic ISSN: 1434-9949
DOI
https://doi.org/10.1007/s10067-011-1765-7

Other articles of this Issue 10/2011

Clinical Rheumatology 10/2011 Go to the issue

Review Article

Usefulness of whole-body fluorine-18-fluorodeoxyglucose positron emission tomography in patients with large-vessel vasculitis: a systematic review

Original Article

Lack of cardiovascular risk assessment in inflammatory arthritis and systemic lupus erythematosus patients at a tertiary care center

Original Article

Lipid profile in Tunisian patients with rheumatoid arthritis

Original Article

Additive effects of low-level laser therapy with exercise on subacromial syndrome: a randomised, double-blind, controlled trial

Brief Report

Comparison of indirect immunofluorescence and multiplex antinuclear antibody screening in systemic sclerosis

Original Article

Normal autonomic nervous system responses in uncomplicated familial Mediterranean fever: a comparative case–control study
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits